Roivant Announces Positive PHocus Results for Mosliciguat

Roivant reported positive data from a Phase 2 study of mosliciguat, showing significant improvements in pulmonary vascular resistance and other clinical endpoints, with new enrollment underway for a Phase 3 study. The company expects to present results at the European Respiratory Society International Congress.